Medical devices, healthcare technology and the business of care
510(k) clearance · K253606

NanoZoomer S20MD Slide scanner system; NanoZoomer S360MD Slide scanner system

Hamamatsu Photonics K.K. · Decision date Jul 15, 2026

FDA DECISIONK253606

What did the FDA decide?

FDA records K253606 as a 510(k) premarket notification, with a decision dated Jul 15, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Pathology
Decision date
Jul 15, 2026

FDA source record

Regulatory record facts

Identifier
K253606
Regulatory pathway
510(k) premarket notification
Product code
PSY
Decision code
SESE
Decision date
Jul 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Whole Slide Imaging System.

Product code
PSY
FDA device class
2

FDA decision timeline

  1. K253606 received

    Application receipt date recorded by FDA.

  2. K253606 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code PSY

Product / regulatory recordCompanyPathwayDecision dateSource
Leica Biosystems Imaging, Inc.510(k) clearanceAug 7, 2026FDA
Hamamatsu Photonics K.K.510(k) clearanceJul 22, 2026FDA
VirasightK251952
Virasoft Corporation510(k) clearanceJul 17, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Hamamatsu Photonics K.K.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Hamamatsu City

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records